Bristol-Myers Squibb Company
) recently announced that it has inked a deal with UK-based
company Reckitt Benckiser Group plc for three years. As per the
terms of the deal, Reckitt Benckiser will get exclusive rights to
commercialize several over-the-counter (OTC) drugs in
Bristol-Myers' portfolio targeting Latin American markets
(primarily Mexico and Brazil).
The products covered under the agreement include Picot (antacid),
Tempra (pain and fever), Micostatin (antifungal), Graneodin
(cough and cold), Dermodex (rash), Luftal (gas) and Naldecon
(cold and flu symptoms).
As per the terms of the agreement, Bristol-Myers will receive an
upfront payment of $438 million from Reckitt Benckiser.
Additionally, Bristol-Myers will also be eligible to receive
royalties of the sales of products covered under the agreement.
The agreement includes an embedded option as per which Reckitt
Benckiser can purchase all the right to these products for $44
million at the end of 3 years.
We are positive on the deal. We believe that Bristol-Myers will
continue pursuing deals and acquisitions throughout 2013 to
strengthen its portfolio thereby minimizing the impact of
Even though the genericization of Plavix and Avapro has resulted
in a significant loss of revenues for Bristol-Myers, we believe
that the company's diversified business model combined with its
strong financial position will help in countering the
The company got a boost with the US approval of its
anti-clotting drug Eliquis (apixaban) in Jan 2013. Moreover, in
Nov 2012, type II diabetes drug, Forxiga, was approved in the EU.
BAYER A G -ADR (BAYRY): Free Stock Analysis
BRISTOL-MYERS (BMY): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.
Bristol-Myers carries a Zacks Rank #3 (Hold). However, other
large cap pharma stocks such as
Eli Lilly and Company
) look more attractive and carry a Zacks Rank #2 (Buy).